MX2016006329A - Composiciones solidas de trigliceridos y usos de estas. - Google Patents

Composiciones solidas de trigliceridos y usos de estas.

Info

Publication number
MX2016006329A
MX2016006329A MX2016006329A MX2016006329A MX2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A MX 2016006329 A MX2016006329 A MX 2016006329A
Authority
MX
Mexico
Prior art keywords
solid compositions
triglycerides
triheptanoin
spray
drying
Prior art date
Application number
MX2016006329A
Other languages
English (en)
Inventor
Emil Kakkis
Steven Jungles
Klopp John
Morris Gabrielle
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MX2016006329A publication Critical patent/MX2016006329A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención incluye composiciones sólidas de triglicéridos con uno o más ácidos grasos, como triheptanoina y fenilbutirato de glicerol, y sus usos terapéuticos; las composiciones sólidas se pueden preparar mediante secado por pulverización u otros procesos.
MX2016006329A 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas. MX2016006329A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14
PCT/US2014/065693 WO2015073816A1 (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Publications (1)

Publication Number Publication Date
MX2016006329A true MX2016006329A (es) 2016-09-06

Family

ID=53058066

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006329A MX2016006329A (es) 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas.
MX2021001790A MX2021001790A (es) 2013-11-14 2016-05-13 Composiciones solidas de trigliceridos y usos de estas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001790A MX2021001790A (es) 2013-11-14 2016-05-13 Composiciones solidas de trigliceridos y usos de estas.

Country Status (18)

Country Link
US (3) US20160243071A1 (es)
EP (2) EP3782610A1 (es)
JP (3) JP2017501972A (es)
KR (1) KR102291310B1 (es)
CN (2) CN113181158A (es)
AR (1) AR099353A1 (es)
AU (1) AU2014348470B2 (es)
CA (2) CA3197154A1 (es)
CL (1) CL2016001130A1 (es)
ES (1) ES2833294T3 (es)
IL (1) IL245588B (es)
MX (2) MX2016006329A (es)
MY (1) MY177028A (es)
PE (1) PE20161024A1 (es)
PH (1) PH12016500821A1 (es)
RU (1) RU2016123169A (es)
TW (1) TWI640327B (es)
WO (1) WO2015073816A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113181158A (zh) * 2013-11-14 2021-07-30 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途
WO2020041871A1 (en) * 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
EP0858441B1 (en) * 1995-02-07 2001-05-09 Brusilow Enterprises, LLC Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
ATE303079T1 (de) * 1999-02-05 2005-09-15 Baylor Res Inst Nahrungsergänzung oder pharmazeutische zusammensetzung enthaltend triglyceride bestehend aus fettsäuren mit 7 kohlenstoffatomen
EP1628622A4 (en) * 2003-05-20 2008-12-17 Baylor Res Inst FIVE AND FIFTH CARBON FATTY ACIDS FOR THE TREATMENT OF METABOLISM DISORDERS AND AS FOOD SUPPLEMENTS
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
CA2573054C (en) * 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CA2599667C (en) * 2005-03-10 2014-12-16 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxy carboxylic acids
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
CN101484148A (zh) * 2006-02-10 2009-07-15 斯博茨科姆丹麦私人有限公司 包衣片剂及其制备方法和相关用途
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
US20110306663A1 (en) * 2010-06-14 2011-12-15 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
JP6073898B2 (ja) 2011-09-30 2017-02-01 ハイペリオン セラピューティクス，インコーポレイテッド 窒素捕集薬の治療監視の方法
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
EP2838522B1 (en) 2012-04-16 2024-02-21 University of Pittsburgh - Of the Commonwealth System of Higher Education Phenylbutyrate for the treatment of medium-chain acyl-coa dehydrogenase deficiency
US9468229B2 (en) 2012-12-13 2016-10-18 National Institute Of Health And Medical Research Triheptanoin for the treatment of glucose transport 1 deficiency
CN113181158A (zh) * 2013-11-14 2021-07-30 奥特吉尼克斯制药公司 三酸甘油酯的固体组合物及其用途

Also Published As

Publication number Publication date
CN113181158A (zh) 2021-07-30
AU2014348470A1 (en) 2016-05-26
EP3068383A4 (en) 2017-11-08
RU2016123169A (ru) 2017-12-19
EP3068383A1 (en) 2016-09-21
PE20161024A1 (es) 2016-11-10
CA2929688C (en) 2023-06-13
MX2021001790A (es) 2021-04-19
KR20160084407A (ko) 2016-07-13
EP3782610A1 (en) 2021-02-24
AR099353A1 (es) 2016-07-20
JP2020111585A (ja) 2020-07-27
US20160243071A1 (en) 2016-08-25
KR102291310B1 (ko) 2021-08-23
CA2929688A1 (en) 2015-05-21
IL245588B (en) 2021-08-31
ES2833294T3 (es) 2021-06-14
TWI640327B (zh) 2018-11-11
AU2014348470B2 (en) 2020-01-30
IL245588A0 (en) 2016-06-30
JP2017501972A (ja) 2017-01-19
CN105764497A (zh) 2016-07-13
JP2022107017A (ja) 2022-07-20
US20200069631A1 (en) 2020-03-05
CL2016001130A1 (es) 2017-01-20
WO2015073816A1 (en) 2015-05-21
PH12016500821A1 (en) 2016-06-13
US20230181513A1 (en) 2023-06-15
CA3197154A1 (en) 2015-05-21
MY177028A (en) 2020-09-02
EP3068383B1 (en) 2020-09-16
TW201609189A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
CL2016002772A1 (es) Composiciones de insulina de rápida acción
NZ730865A (en) Peptides having anti-inflammatory properties
EP2981166A4 (en) Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2014113729A8 (en) Methods of treating cholangiocarcinoma
MX2019012271A (es) Acidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide.
MX366561B (es) Composicion que contiene minoxidil para el crecimiento del pelo.
DK3384902T3 (da) Fremgangsmåder, sammensætninger og indretninger til opfyldelse af diætmæssige behov for fedtsyre
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3068500A4 (en) Fertilizer compositions and methods of making and using the same
IN2014DN07483A (es)
IL245479B (en) Suspension compositions of physiologically active phenolic compounds and methods for their preparation and use
SA515361092B1 (ar) تركيبات راسكادوتريل الدهنية
IN2013MU03641A (es)
EP3232770A4 (en) Generation of transgenic canola with low or no saturated fatty acids
MX2017008450A (es) Composiciones inhibidoras de nitrificacion microencapsuladas.
CA2875305C (en) Fbxo3 inhibitors
MX2021001790A (es) Composiciones solidas de trigliceridos y usos de estas.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
MX2015016603A (es) Composiciones de corticosteroides.
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
IN2014DN06617A (es)
BR112016028561A8 (pt) composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
PT3097921T (pt) Composições que compreendem geraniol e gengibre seco para utilização no tratamento da síndrome do intestino irritável